Literature DB >> 9807701

The molecular and cellular biology of pancreatic cancer.

R A Perugini1, T P McDade, F J Vittimberga, M P Callery.   

Abstract

Adenocarcinoma of the pancreas carries a grave prognosis for affected patients. Certain oncogenes (K-ras and HER-2/neu) are mutated in a large proportion of these aggressive tumors. Adenocarcinoma of the pancreas has also been associated with loss of tumor suppressor genes (p53, DPC4, p16/MTS), either by deletion or by mutation and loss of function. Growth factors (EGF, TGF-alpha, HGF) and growth factor receptors (EGF-R, c-met, CCK) are expressed at levels not found in the normal pancreas. Finally, factors important for angiogenesis (FGF, integrins, selectins) are likely to play an important role in the growth and metastasis of clinically relevant tumors. This review attempts to summarize and assimilate current research into the molecular and cellular biology of pancreatic cancer.

Entities:  

Mesh:

Year:  1998        PMID: 9807701     DOI: 10.1615/critreveukargeneexpr.v8.i3-4.70

Source DB:  PubMed          Journal:  Crit Rev Eukaryot Gene Expr        ISSN: 1045-4403            Impact factor:   1.807


  10 in total

1.  In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice.

Authors:  C J Bruns; M T Harbison; H Kuniyasu; I Eue; I J Fidler
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

2.  Sodium salicylate inhibits proliferation and induces G1 cell cycle arrest in human pancreatic cancer cell lines.

Authors:  R A Perugini; T P McDade; F J Vittimberga; A J Duffy; M P Callery
Journal:  J Gastrointest Surg       Date:  2000 Jan-Feb       Impact factor: 3.452

3.  Significant growth inhibition of orthotopic pancreatic ductal adenocarcinoma by CpG oligonucleotides in immunodeficient mice.

Authors:  J Tepel; O Dagvadorj; M Kapischke; B Sipos; A Leins; B Kremer; H Kalthoff
Journal:  Int J Colorectal Dis       Date:  2005-08-16       Impact factor: 2.571

4.  A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells.

Authors:  Z Su ; I V Lebedeva; R V Gopalkrishnan; N I Goldstein; C A Stein; J C Reed; P Dent; P B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

5.  Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis.

Authors:  K M Detjen; K Farwig; M Welzel; B Wiedenmann; S Rosewicz
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

6.  Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase.

Authors:  K A Furge; D Kiewlich; P Le; M N Vo; M Faure; A R Howlett; K E Lipson; G F Vande Woude; C P Webb
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-04       Impact factor: 11.205

7.  PI-3' kinase and NF-kappaB cross-signaling in human pancreatic cancer cells.

Authors:  S A Shah; M W Potter; M H Hedeshian; R D Kim; R S Chari; M P Callery
Journal:  J Gastrointest Surg       Date:  2001 Nov-Dec       Impact factor: 3.452

Review 8.  mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine.

Authors:  Pankaj Gupta; Zao-zhong Su; Irina V Lebedeva; Devanand Sarkar; Moira Sauane; Luni Emdad; Michael A Bachelor; Steven Grant; David T Curiel; Paul Dent; Paul B Fisher
Journal:  Pharmacol Ther       Date:  2006-02-07       Impact factor: 12.310

9.  Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer.

Authors:  William W Tseng; Adriana Deganutti; May N Chen; Romaine E Saxton; Carson D Liu
Journal:  J Gastrointest Surg       Date:  2002 Nov-Dec       Impact factor: 3.267

Review 10.  Implications of growth factor alterations in the treatment of pancreatic cancer.

Authors:  Márk Juhász; Barbara Nitsche; Peter Malfertheiner; Matthias P A Ebert
Journal:  Mol Cancer       Date:  2003-01-07       Impact factor: 27.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.